Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020
| Technical / White Paper
This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...
The complexity of processes to manufacture cell and gene therapy medicinal products can cause confusion around definitions of raw materials, starting materials,...
Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020
| Technical / White Paper
We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...
Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020
| Technical / White Paper
In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...
Eppendorf for Bioprocess – Solutions that grow with you | 29-Oct-2020
| Application Note
Effective drug discovery and development relies on the availability of predictive preclinical model systems. Technologies based on human induced pluripotent...
Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...
With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization...
Baxter BioPharma Solutions | 19-Oct-2020
| Technical / White Paper
The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...
Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with...
Anion exchange chromatography is an important step for viral clearance of monoclonal antibodies. Natrix® Q chromatography membrane improves cost-efficiency....
The MilliporeSigma organization is dedicated to supporting your cell and gene therapy from early phase through product release. Not only does our BioReliance®...
Take the Right Path Upstream with MilliporeSigma | 01-Oct-2020
| Technical / White Paper
Development of a high-producing cell line supported by a robust upstream process are critical early steps in the production of monoclonal antibodies (mAbs)....
In January 2020, the United States Food and Drug Administration (FDA) released several new or updated guidance documents pertaining to human gene therapy...
Viral contamination is a risk for all biotechnology products. Recent studies have shown that viral retentive filtration is one of the most robust steps...
